Ralofen Effects on Serum Lipids in Menopause Women

BACKGROUND AND OBJECTIVE: Raloxifen is used widely to prevent menopause complications. Hyperlipidemia is a risk factor for coronary heart disease in menopausal women. There are controversies about raloxifen effects on serum lipids, so this study was done to determine the effects of raloxifen (ralofe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M Javadian, Z Bouzari, F Tirehdast
Formato:	article
Lenguaje:	EN FA
Publicado:	Babol University of Medical Sciences 2010
Materias:	osteoprosis ralofen serum lipid menopause Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ab37deb27af04736b925a85fd77be257
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab37deb27af04736b925a85fd77be257
record_format	dspace
spelling	oai:doaj.org-article:ab37deb27af04736b925a85fd77be2572021-11-10T09:00:07ZRalofen Effects on Serum Lipids in Menopause Women1561-41072251-7170https://doaj.org/article/ab37deb27af04736b925a85fd77be2572010-01-01T00:00:00Zhttp://jbums.org/article-1-3368-en.htmlhttps://doaj.org/toc/1561-4107https://doaj.org/toc/2251-7170BACKGROUND AND OBJECTIVE: Raloxifen is used widely to prevent menopause complications. Hyperlipidemia is a risk factor for coronary heart disease in menopausal women. There are controversies about raloxifen effects on serum lipids, so this study was done to determine the effects of raloxifen (ralofen) on serum lipids of the menopausal women.METHODS: This before-after interventional study was done on 50 menopausal women that returned to menopausal clinic of Yahyanejad hospital in Babol in 2008. Inclusion criteria were 45–60 years old and past of one year of last menstural period. Exclusion criteria were history of cancer, abnormal uterus bleeding, clotting dysfunction, use of androgen, corticosteroid and estrogen, renal failure, chronic and acute disease of liver, history of deep vein thrombosis and cardiovascular disease. Patient received ralofen (product by Aboryhan company) 60 mg/day for three months. Serum lipid level measured in three times include: before treatment, one month and three month later. FINDINGS: The mean age (±SD) of the patients was 53.2±3.7 and the median time of last menstural period was 6 years. The mean level of serum triglyceride (mg/dl) of menopausal women was significant (p=0.012) before treatment (159.6±36.1 mg/dl), one month after treatment (162.9±34.8 mg/dl) and three month after treatment (170.8±41.7 mg/dl). So the mean level of serum cholesterol (mg/dl) of menopausal women was significant (p=0.000) before treatment (193.6±22.2 mg/dl), one month after treatment (198.6±24.9 mg/dl) and three month after treatment (202.1±26.7 mg/dl).The mean level of serum LDL (mg/dl) of menopausal women was not significant (p=0.152) before treatment (114.6±28.3 mg/dl), one month after treatment (118.8±29.6 mg/dl) and three month after treatment (113.9±26.7 mg/dl). So the mean level of serum HDL (mg/dl) of menopausal women was not significant before treatment (47.8±9.3 mg/dl), one month after treatment (46.7±8.5 mg/dl) and three months after treatment (48.2±5.8 mg/dl). CONCLUSION: This study showed that ralofen had no significant effects on serum lipids levels and triglyceride and cholesterol increased were in normal and borderline limits that don have clinical importance.M Javadian,Z BouzariF TirehdastBabol University of Medical Sciencesarticleosteoprosisralofenserum lipidmenopauseMedicineRMedicine (General)R5-920ENFAMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, Vol 11, Iss 6, Pp 16-20 (2010)
institution	DOAJ
collection	DOAJ
language	EN FA
topic	osteoprosis ralofen serum lipid menopause Medicine R Medicine (General) R5-920
spellingShingle	osteoprosis ralofen serum lipid menopause Medicine R Medicine (General) R5-920 M Javadian, Z Bouzari F Tirehdast Ralofen Effects on Serum Lipids in Menopause Women
description	BACKGROUND AND OBJECTIVE: Raloxifen is used widely to prevent menopause complications. Hyperlipidemia is a risk factor for coronary heart disease in menopausal women. There are controversies about raloxifen effects on serum lipids, so this study was done to determine the effects of raloxifen (ralofen) on serum lipids of the menopausal women.METHODS: This before-after interventional study was done on 50 menopausal women that returned to menopausal clinic of Yahyanejad hospital in Babol in 2008. Inclusion criteria were 45–60 years old and past of one year of last menstural period. Exclusion criteria were history of cancer, abnormal uterus bleeding, clotting dysfunction, use of androgen, corticosteroid and estrogen, renal failure, chronic and acute disease of liver, history of deep vein thrombosis and cardiovascular disease. Patient received ralofen (product by Aboryhan company) 60 mg/day for three months. Serum lipid level measured in three times include: before treatment, one month and three month later. FINDINGS: The mean age (±SD) of the patients was 53.2±3.7 and the median time of last menstural period was 6 years. The mean level of serum triglyceride (mg/dl) of menopausal women was significant (p=0.012) before treatment (159.6±36.1 mg/dl), one month after treatment (162.9±34.8 mg/dl) and three month after treatment (170.8±41.7 mg/dl). So the mean level of serum cholesterol (mg/dl) of menopausal women was significant (p=0.000) before treatment (193.6±22.2 mg/dl), one month after treatment (198.6±24.9 mg/dl) and three month after treatment (202.1±26.7 mg/dl).The mean level of serum LDL (mg/dl) of menopausal women was not significant (p=0.152) before treatment (114.6±28.3 mg/dl), one month after treatment (118.8±29.6 mg/dl) and three month after treatment (113.9±26.7 mg/dl). So the mean level of serum HDL (mg/dl) of menopausal women was not significant before treatment (47.8±9.3 mg/dl), one month after treatment (46.7±8.5 mg/dl) and three months after treatment (48.2±5.8 mg/dl). CONCLUSION: This study showed that ralofen had no significant effects on serum lipids levels and triglyceride and cholesterol increased were in normal and borderline limits that don have clinical importance.
format	article
author	M Javadian, Z Bouzari F Tirehdast
author_facet	M Javadian, Z Bouzari F Tirehdast
author_sort	M Javadian,
title	Ralofen Effects on Serum Lipids in Menopause Women
title_short	Ralofen Effects on Serum Lipids in Menopause Women
title_full	Ralofen Effects on Serum Lipids in Menopause Women
title_fullStr	Ralofen Effects on Serum Lipids in Menopause Women
title_full_unstemmed	Ralofen Effects on Serum Lipids in Menopause Women
title_sort	ralofen effects on serum lipids in menopause women
publisher	Babol University of Medical Sciences
publishDate	2010
url	https://doaj.org/article/ab37deb27af04736b925a85fd77be257
work_keys_str_mv	AT mjavadian ralofeneffectsonserumlipidsinmenopausewomen AT zbouzari ralofeneffectsonserumlipidsinmenopausewomen AT ftirehdast ralofeneffectsonserumlipidsinmenopausewomen
_version_	1718440318690394112

Ralofen Effects on Serum Lipids in Menopause Women

Ejemplares similares